Sign In
Buy FENC
$9.14
-0.84 (-8.42%)
At Close: Jun 03, 2026
Adherex Technologies Inc. (FENC) Reports Q4 Loss, Misses Revenue Estimates
09:11am, Tuesday, 24'th Mar 2026
Adherex Technologies Inc. (FENC) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of $0.03. This compares to a loss of $0.06 per share a year ago.
Fennec Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
07:00am, Tuesday, 24'th Mar 2026
~ Delivered Record Annual Revenue with Full-Year Net PEDMARK ® Product Sales of $44.6 Million, Representing 50% Year-Over-Year Growth, and Q4 2025 Net Product Sales of $13.8 Million, Representing 7
Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
04:40pm, Monday, 23'rd Mar 2026
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) will release earnings results for its fourth quarter, before the opening bell on Tuesday, March 24.
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2025 Financial Results on March 24, 2026
07:08am, Wednesday, 18'th Mar 2026
RESEARCH TRIANGLE PARK, N.C., March 18, 2026 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Com
Fennec Pharmaceuticals Announces Clinical Research Collaboration with Tampa General Hospital Cancer Institute
07:05am, Wednesday, 04'th Mar 2026
Study is Real-World Evaluation of the Clinical Utility of Sodium Thiosulfate Injection (PEDMARK®) in Reducing the Risk of Ototoxicity in Adolescent and Young Adult (AYA) and Adult Patients with Non-
Adherex Technologies Inc. (FENC) Earnings Expected to Grow: What to Know Ahead of Q4 Release
11:00am, Monday, 02'nd Mar 2026
Adherex Technologies (FENC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Administration of PEDMARK Approximately Six Hours After Cisplatin was Shown to Be Safe and Easily Integrated into Care for Adults with Head and Neck Cancers (HNC) - - Early Signals of Hearing Preser
Brokerages Set Adherex Technologies Inc. (NASDAQ:FENC) PT at $14.50
02:24am, Friday, 13'th Feb 2026
Shares of Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the company
Pre-Market Stock Futures: Futures are trading higher after a wild Wednesday that saw the market rally hard on the open on the non-farm payrolls print that blew away estimates, despite a significant de
Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)
05:44pm, Friday, 26'th Dec 2025
NEW YORK, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Southpoint Capital Advisors LP (“Southpoint”), acting on behalf of certain Southpoint funds for which it serves as investment manager, announces that on
Adherex Technologies Inc. (NASDAQ:FENC) Given Consensus Recommendation of “Hold” by Analysts
03:30am, Monday, 22'nd Dec 2025
Adherex Technologies Inc. (NASDAQ: FENC - Get Free Report) has been given a consensus recommendation of "Hold" by the five brokerages that are covering the stock, Marketbeat.com reports. One investmen
Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026
10:01pm, Sunday, 21'st Dec 2025
Fennec Pharmaceuticals is a commercial-stage oncology supportive-care company centered on Pedmark/Pedmarqsi. This drug helps reduce cisplatin-induced ototoxicity in pediatric patients who are battling
– City of Hope to Evaluate PEDMARK ® for Reducing Ototoxicity in Adult Men with Stage II-III Metastatic Testicular Germ Cell Tumors –
Pedmark Delivers In Japan Study — Less Hearing Loss, Same Cancer-Fighting Power
11:56am, Tuesday, 02'nd Dec 2025
Pedmark cut cisplatin-related hearing loss in a Japan trial, with strong safety and no impact on tumor response, supporting plans for Japan registration.
– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK ® when Compared with Historically Reported Rate
